<DOC>
	<DOC>NCT00938717</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of linaclotide administered to patients with Irritable Bowel Syndrome with Constipation (IBS-C).</brief_summary>
	<brief_title>Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12lead ECG, or clinical laboratory tests Patient meets protocol criteria for diagnosis of IBSC Patient demonstrates continued IBSC through Pretreatment Period Patient is compliant with IVRS Patient has history of loose or watery stools Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility Patient has any protocolexcluded or clinically significant medical or surgical history that could confound the study assessments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>IBS</keyword>
</DOC>